EXCLUSIVE: Grifols CEO Reveals Company's Vision For Curing Rare Diseases

by

Diablo

EXCLUSIVE: Grifols CEO Reveals Company's Vision For Curing Rare Diseases

Verkkorobin alderman faces an agonizing reality: Gene therapy might cure her son camden’s rare, inherited immune deficiency. But it’s not available to him. Verkkothe family behind grifols, the €6bn spanish healthcare group rocked by fraud allegations earlier this year, is exploring a bid to take the company private. That is exactly what scientists expect. Verkkothis team will be under the leadership of a new ceo, nacho abia, who will join the company on april 1, 2024, while i will continue to serve as executive chairperson. Verkkonacho abia begins tenure as new grifols ceo. Abia will focus on continuing to accelerate the company’s growth, furthering its operational excellence and continuing its deleveraging plan. Thomas glanzmann continues as. Verkkoa bone marrow transplant can cure some cases of the illness, but many children lack a suitable donor. Other existing therapies only partially restore. Verkkothe grifols family and canadian fund brookfield have agreed to evaluate a possible joint takeover bid for beleaguered spanish drugmaker grifols.

Executive chairman of Spanish pharma company Grifols resigns | Reuters

Related Post